A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature.

Halperin, William; Weiss, Walter; Altman, Ronald; Diamond, M A; Black, Kenneth; Iaci, A W; Black, Henry C.; Goldfield, Martin

doi:10.2105/ajph.69.12.1247

Cited by 45 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential to spare dose by i.d. administration was suggested over 25 years ago (10,20,24) and has received renewed attention recently (8,29,31). However, the lack of a reproducible and easy-to-use i.d.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

Alarcon

Hartley

Harvey

et al. 2007

Clin Vaccine Immunol

133

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…delivery have been reported. Intradermal delivery of influenza vaccine was investigated in humans in the late 1970s using monovalent and bivalent vaccine preparations (10,20,24). In these early studies, i.d.…”

mentioning

confidence: 99%

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

Alarcon

Hartley

Harvey

et al. 2007

Clin Vaccine Immunol

133

View full text Add to dashboard Cite

“…4,5) Therefore, TCI is expected to enable efficient vaccination with the least amount of antigen. [6][7][8] The stratum corneum, the outermost layer of the epidermis, serves as a barrier that prevents chemicals and exogenous substances from entering the body. As the barrier function interferes with the success of TCI, a number of physical techniques for the enhancement of antigen delivery into the skin have been investigated.…”

mentioning

confidence: 99%

Application of Microneedles to Skin Induces Activation of Epidermal Langerhans Cells and Dermal Dendritic Cells in Mice

Takeuchi

Nomoto

Watanabe

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

An adequate immune response to percutaneous vaccine application is generated by delivery of sufficient amounts of antigen to skin and by administration of toxin adjuvants or invasive skin abrasion that leads to an adjuvant effect. Microneedles penetrate the stratum corneum, the outermost layer of the skin, and enable direct delivery of vaccines from the surface into the skin, where immunocompetent dendritic cells are densely distributed. However, whether the application of microneedles to the skin activates antigen-presenting cells (APCs) has not been demonstrated. Here we aimed to demonstrate that microneedles may act as a potent physical adjuvant for successful transcutaneous immunization (TCI). We prepared samples of isolated epidermal and dermal cells and analyzed the expression of major histocompatibility complex (MHC) class II and costimulatory molecules on Langerhans or dermal dendritic cells in the prepared samples using flow cytometry. The expression of MHC class II and costimulatory molecules demonstrated an upward trend in APCs in the skin after the application of 500-and 300-µm microneedles. In addition, in the epidermal cells, application of microneedles induced more effective activation of Langerhans cells than did an invasive tapestripping (positive control). In conclusion, the use of microneedles is likely to have a positive effect not only as an antigen delivery system but also as a physical technique inducing an adjuvant-like effect for TCI.

show abstract

“…The influenza vaccine was usually administered subcutaneously in Japan. One reason for low humoral immune response might be subcutaneous administration because the immunogenicity of the intradermal route seems superior to that of the subcutaneous route 21 One of 16 pediatricians (6.3%) at our hospital contracted pandemic influenza A (H1N1) after the vaccination, and 4 of 154 other medical doctors contracted it (2.6%). At least, pediatricians should be protected against pandemic influenza by a vaccine of particularly high immunogenicity.…”

Section: Discussionmentioning

confidence: 99%

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Hata

Mano

Nakamura

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Immunization of health care personnel (HCP) is critically important to reduce healthcare-associated influenza infections substantially. During 2009During -2010 of all HCP at Kitano Hospital, Osaka, Japan, including 94% of pediatricians, received the monovalent unadjuvanted influenza A (H1N1) pdm09 vaccine.We evaluated the vaccine's immunogenicity. Sixteen pediatricians received 15 mg hemagglutinin antigen subcutaneously. Antibody titer assays were conducted using hemagglutination-inhibition antibody assay on days 0 and 21 and at 5 mo after vaccination. Seroprotection rates, seroconversion rates, and geometric mean titer folds at 21 d were, respectively, 43.8%, 43.8% and 5.4 in all subjects, 70.0%, 70.0% and 8.0 in subjects aged 27-34 y, and 0.0%, 0.0% and 8.0 in subjects aged $ 35 y. None of the latter group met the European Medicines Agency criteria.We hope to adopt intradermal routes and further the development of the influenza vaccine using new technology to improve immunogenicity in Japan.

show abstract

A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature.

Cited by 45 publications

References 16 publications

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

Application of Microneedles to Skin Induces Activation of Epidermal Langerhans Cells and Dermal Dendritic Cells in Mice

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Contact Info

Product

Resources

About